Healthy
Conditions
Keywords
Wine
Brief summary
Healthy pre-menopausal women will be recruited in order to test the effects of red wine and white wine on blood estrogen and progesterone levels. The women will be randomized and rotated through two different treatments (red wine, white wine). Estrone and estradiol are hormones in the category of estrogens. It is known that the bodies of both men and women may convert (or aromatize) a certain amount of naturally occurring testosterone into estrogen. Aromatase inhibitors have been used to prevent this conversion, or aromatization, of testosterone into estrogen, in the treatment of estrogen-dependent breast cancer in women. This inhibition leads to a marked decrease in estrogen (estradiol and estrone) levels. Naturally occurring aromatase inhibitors include grapes, grape juice, and red, but not white wine. The aromatase inhibitory effects are attributed to wine phytochemicals and not to alcohol. Based upon this information, the investigators will monitor the estrogen levels at various phases in the menstrual cycles of women since hormone levels naturally vary throughout the menstrual cycle. Several epidemiologic studies have found that there is a correlation with moderate to high levels of alcohol consumption and breast cancer. Therefore, study participants will be asked to drink only a eight ounces of wine which should have minimal or no risk for the development of breast cancer.
Interventions
OTHERRed Wine
8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
OTHERWhite Wine
8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
Sponsors
Cedars-Sinai Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. female 2. pre-menopausal with regular ovulatory cycles for 12 months prior to the study 3. willingness and ability to participate in study requiring alcohol consumption 4. in general good health 5. BMI of 18.5-35 6. on regular, unrestricted diet 7. not currently, or within the past 3 months, using oral contraceptives or other hormone replacement therapy
Exclusion criteria
1. male 2. irregular menstrual cycles or vasomotor symptoms within the last 12 months 3. pregnant (or breast feeding) 4. any hormone therapy including phytoestrogens, oral contraceptives, SERMs (selective estrogen receptor modulators), or androgens (or precursors) for three months prior to the study 5. history of alcohol abuse 6. history of any estrogen-dependent neoplasia 7. high intake of dietary soy products 8. Minors \< age 21 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood estrogen and progesterone levels | 15 minutes |
Countries
United States
Outcome results
None listed